| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (NCT07175415) | Princess Maxima Center for Pediatric Oncology | 2026-10-01 |
| An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma (NCT07399821) | Princess Maxima Center for Pediatric Oncology | 2025-11-05 |
| HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (NCT05751044) | Princess Maxima Center for Pediatric Oncology | 2025-10-01 |
| HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (NCT05745714) | Princess Maxima Center for Pediatric Oncology | 2025-10-01 |
| The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies (NCT07020260) | Princess Maxima Center for Pediatric Oncology | 2025-09-01 |
| Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma (NCT06485947) | Princess Maxima Center for Pediatric Oncology | 2025-01-28 |
| CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients (NCT06262438) | Princess Maxima Center for Pediatric Oncology | 2024-02-06 |
| HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (NCT05658640) | Princess Maxima Center for Pediatric Oncology | 2023-11-14 |
| HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (NCT05740449) | Princess Maxima Center for Pediatric Oncology | 2023-10-01 |
| CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients (NCT05994690) | Princess Maxima Center for Pediatric Oncology | 2023-07-14 |
| International Leukemia Target Board (NCT05270096) | Princess Maxima Center for Pediatric Oncology | 2022-12-31 |
| Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (NCT05327894) | Princess Maxima Center for Pediatric Oncology | 2022-12-15 |
| Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors (NCT04925609) | Princess Maxima Center for Pediatric Oncology | 2022-08-18 |
| Vyxeos® With Clofarabine for Pediatric AML (NCT07156435) | Princess Maxima Center for Pediatric Oncology | 2020-11-06 |
| Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients. (NCT05740150) | Princess Maxima Center for Pediatric Oncology | 2020-10-27 |